The Food and Drug Administration (FDA) announced that Factive (gemifloxacin mesylate; LG Life Sciences) is currently in shortage.
Factive 320mg tablets in 5- and 7-count blister packs are currently in shortage due to a legal dispute regarding license to manufacture and distribute the drug. There is currently no estimated duration of the shortage.
Factive is a quinolone antibiotic indicated for the treatment of susceptible infections including acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia in adults aged ≥18 years.
For more information call For more information call (888) 463-6332 or visit FDA.gov.
This article originally appeared on MPR